Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice

被引:3
|
作者
Sarawar, Sally [1 ]
Gabaglia, Claudia R. [1 ]
Sanchez, Adriana [1 ]
Hatta, Yasuko [2 ]
Dias, Peter [1 ]
Neumann, Gabriele [3 ]
Kawaoka, Yoshihiro [3 ,4 ,5 ]
Bilsel, Pamuk [2 ]
机构
[1] Biomed Res Inst Southern Calif, Oceanside, CA 92056 USA
[2] FluGen Inc, Madison, WI 53711 USA
[3] Univ Wisconsin, Influenza Res Inst, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53711 USA
[4] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Microbiol & Immunol,Div Virol, Tokyo 1088639, Japan
[5] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Special Pathogens, Tokyo 1088639, Japan
基金
美国国家卫生研究院;
关键词
influenza; vaccine; duration; antibody; heterosubtypic; depletion; A VIRUS; IMMUNITY; INFECTION; ANTIBODIES; PROTEIN; CELLS;
D O I
10.3390/vaccines10122131
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Seasonal influenza and the threat of global pandemics present a continuing threat to public health. However, conventional inactivated influenza vaccines (IAVs) provide little cross-protective immunity and suboptimal efficacy, even against well-matched strains. Furthermore, the protection against matched strains has been shown to be of a short duration in both mouse models and humans. M2SR (M2-deficient single-replication influenza virus) is a single-replication vaccine that has been shown to provide effective cross-protection against heterosubtypic influenza viruses in both mouse and ferret models. In the present study, we investigated the duration and mechanism of heterosubtypic protection induced by M2SR in a mouse model. We previously showed that M2SR generated from influenza A/Puerto Rico/8/34 (H1N1) significantly protected C57BL/6 mice against lethal challenge with both influenza A/Puerto Rico/8/34 (H1N1, homosubtypic) and influenza A/Aichi/2/1968 (H3N2, heterosubtypic), whereas the inactivated influenza vaccine provided no heterosubtypic protection. The homosubtypic protection induced by M2SR was robust and lasted for greater than 1 year, whereas that provided by the inactivated vaccine lasted for less than 6 months. The heterosubtypic protection induced by M2SR was of a somewhat shorter duration than the homosubtypic protection, with protection being evident 9 months after vaccination. However, heterosubtypic protection was not observed at 14 months post vaccination. M2SR has been shown to induce strong systemic and mucosal antibody and T cell responses. We investigated the relative importance of these immune mechanisms in heterosubtypic protection, using mice that were deficient in B cells or mice that were depleted of T cells immediately before challenge. Somewhat surprisingly, the heterosubtypic protection was completely dependent on B cells in this model, whereas the depletion of T cells had no significant effect on survival after a lethal heterosubtypic challenge. While antibody-dependent cellular cytotoxicity (ADCC) has been demonstrated to be important in the response to some influenza vaccines, a lack of Fc receptors did not affect the survival of M2SR-vaccinated mice following a lethal challenge. We examined the influenza proteins targeted by the heterosubtypic antibody response. Shortly after the H1N1 M2SR vaccination, high titers of cross-reactive antibodies to heterosubtypic H3N2 nucleoprotein (NP) and lower titers to the stalk region of the hemagglutinin (HA2) and neuraminidase (NA) proteins were observed. The high antibody titers to heterosubtypic NP persisted one year after vaccination, whereas the antibody titers to the heterosubtypic HA2 and NA proteins were very low, or below the limit of detection, at this time. These results show that the intranasal M2SR vaccine elicits durable protective immune responses against homotypic and heterosubtypic influenza infection not seen with intramuscular inactivated vaccines. Both the homo- and heterosubtypic protection induced by the single-replication vaccine are dependent on B cells in this model. While the homosubtypic protection is mediated by antibodies to the head region of HA, our data suggest that the heterosubtypic protection for M2SR is due to cross-reactive antibodies elicited against the NP, HA2, and NA antigens that are not targeted by current seasonal influenza vaccines.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein
    Stanekova, Z.
    Kiraly, J.
    Stropkovska, A.
    Mikuskova, T.
    Mucha, V.
    Kostolansky, F.
    Vareckova, E.
    ACTA VIROLOGICA, 2011, 55 (01) : 61 - 67
  • [22] A universal Influenza A vaccine based on M2 mediates complete protection from lethal infection in mice
    Schmitz, N.
    Saudan, P.
    Bachmann, M. F.
    SWISS MEDICAL WEEKLY, 2007, 137 : 32S - 32S
  • [23] The M2 protein of live, attenuated influenza vaccine encodes a mutation that reduces replication in human nasal epithelial cells
    Wohigemuth, Nicholas
    Ye, Yang
    Fenstermacher, Katherine J.
    Liu, Hsuan
    Lane, Andrew P.
    Pekosz, Andrew
    VACCINE, 2017, 35 (48) : 6691 - 6699
  • [24] Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza a virus in mice
    Eun-Ha Kim
    Jun-Han Lee
    Philippe Noriel Q Pascua
    Min-Suk Song
    Yun-Hee Baek
    Hyeok-il Kwon
    Su-Jin Park
    Gyo-Jin Lim
    Arun Decano
    Mohammed YE Chowdhury
    Su-Kyung Seo
    Man Ki Song
    Chul-Joong Kim
    Young-Ki Choi
    Virology Journal, 10
  • [25] Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza a virus in mice
    Kim, Eun-Ha
    Lee, Jun-Han
    Pascua, Philippe Noriel Q.
    Song, Min-Suk
    Baek, Yun-Hee
    Kwon, Hyeok-il
    Park, Su-Jin
    Lim, Gyo-Jin
    Decano, Arun
    Chowdhury, Mohammed Y. E.
    Seo, Su-Kyung
    Song, Man Ki
    Kim, Chul-Joong
    Choi, Young-Ki
    VIROLOGY JOURNAL, 2013, 10
  • [26] Novel vaccination of supplementing live attenuated influenza vaccine with M2 ectodomain tandem repeat to confer universal protection
    Lee, Young-tae
    Kim, Min-Chul
    Ko, Eun-Ju
    Lee, Yu-Na
    Kim, Ki-Hye
    Kwon, Young-Man
    Hwang, Hye Suk
    Lee, Youri
    Jung, Yu-Jin
    Kang, Sang
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [27] Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection
    Padilla-Quirarte, H. O.
    Badillo-Godinez, O.
    Gutierrez-Xicotencatl, L.
    Acevedo-Betancur, Y.
    Luna-Andon, J. D.
    Montiel-Hernandez, J. L.
    Lopez-Guerrero, D. V.
    Esquivel-Guadarrama, F.
    VACCINE, 2019, 37 (19) : 2624 - 2633
  • [28] Protection against Multiple Influenza A Virus Strains Induced by Candidate Recombinant Vaccine Based on Heterologous M2e Peptides Linked to Flagellin
    Stepanova, Liudmila A.
    Kotlyarov, Roman Y.
    Kovaleva, Anna A.
    Potapchuk, Marina V.
    Korotkov, Alexandr V.
    Sergeeva, Mariia V.
    Kasianenko, Marina A.
    Kuprianov, Victor V.
    Ravin, Nikolai V.
    Tsybalova, Liudmila M.
    Skryabin, Konstantin G.
    Kiselev, Oleg I.
    PLOS ONE, 2015, 10 (03):
  • [29] PROTECTION OF MICE AGAINST INFLUENZA-A VIRUS CHALLENGE BY VACCINATION WITH BACULOVIRUS-EXPRESSED M2 PROTEIN
    SLEPUSHKIN, VA
    KATZ, JM
    BLACK, RA
    GAMBLE, WC
    ROTA, PA
    COX, NJ
    VACCINE, 1995, 13 (15) : 1399 - 1402
  • [30] Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant
    Zhiwei Sui
    Quanjiao Chen
    Rui Wu
    Hongbo Zhang
    Mei Zheng
    Hanzhong Wang
    Ze Chen
    Archives of Virology, 2010, 155 : 535 - 544